| http://dbpedia.org/ontology/abstract
|
Lerdelimumab (CAT-152, intended trade name … Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2. It was being developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results for that condition.ccessful trial results for that condition.
, Il lerdelimumab o CAT-152, nome commercial … Il lerdelimumab o CAT-152, nome commerciale Trabio, è un anticorpo monoclonale di tipo umano, ad attività immunosoppressiva che viene utilizzato per ridurre le cicatrici post-chirurgia del glaucoma. Il farmaco agisce sull'antigene fattore di crescita trasformante beta 2.e fattore di crescita trasformante beta 2.
, لردليموماب جسم مضاد وحيد النسيلة بشري ودواء مثبط للمناعة كان من المفترض تسميته تجارياً ترابيو (Trabio) ليستخدم في جراحة الزرق لكن التجارب السريرية ألغيت عام 2005 بعد نتائج غير ناجحة.
|
| http://dbpedia.org/ontology/casNumber
|
285985-06-0
|
| http://dbpedia.org/ontology/fdaUniiCode
|
GX1FEU3QSM
|
| http://dbpedia.org/ontology/wikiPageID
|
9132535
|
| http://dbpedia.org/ontology/wikiPageLength
|
2011
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1029723956
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Human +
, http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/TGF_beta_2 +
, http://dbpedia.org/resource/Glaucoma_surgery +
, http://dbpedia.org/resource/Immunosuppressive_drug +
|
| http://dbpedia.org/property/atcPrefix
|
none
|
| http://dbpedia.org/property/casNumber
|
285985
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/legalStatus
|
Development discontinued
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/source
|
u
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/TGF_beta_2 +
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
GX1FEU3QSM
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
458270397
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Monoclonals_for_immune_system +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Immunosuppressants +
, http://dbpedia.org/resource/Template:Antineoplastic-drug-stub +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:TGF%CE%B2_receptor_superfamily_modulators +
, http://dbpedia.org/resource/Template:Monoclonal-antibody-stub +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Fdacite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Monoclonal_antibodies +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antibody +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Lerdelimumab?oldid=1029723956&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Lerdelimumab +
|
| owl:sameAs |
http://it.dbpedia.org/resource/Lerdelimumab +
, http://ar.dbpedia.org/resource/%D9%84%D8%B1%D8%AF%D9%84%D9%8A%D9%85%D9%88%D9%85%D8%A7%D8%A8 +
, http://www.wikidata.org/entity/Q3830773 +
, https://global.dbpedia.org/id/3XxJ2 +
, http://rdf.freebase.com/ns/m.027ywkl +
, http://yago-knowledge.org/resource/Lerdelimumab +
, http://dbpedia.org/resource/Lerdelimumab +
|
| rdf:type |
http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
, http://www.wikidata.org/entity/Q8386 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://umbel.org/umbel/rc/DrugProduct +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
|
| rdfs:comment |
Lerdelimumab (CAT-152, intended trade name … Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2. It was being developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results for that condition.ccessful trial results for that condition.
, Il lerdelimumab o CAT-152, nome commercial … Il lerdelimumab o CAT-152, nome commerciale Trabio, è un anticorpo monoclonale di tipo umano, ad attività immunosoppressiva che viene utilizzato per ridurre le cicatrici post-chirurgia del glaucoma. Il farmaco agisce sull'antigene fattore di crescita trasformante beta 2.e fattore di crescita trasformante beta 2.
, لردليموماب جسم مضاد وحيد النسيلة بشري ودواء مثبط للمناعة كان من المفترض تسميته تجارياً ترابيو (Trabio) ليستخدم في جراحة الزرق لكن التجارب السريرية ألغيت عام 2005 بعد نتائج غير ناجحة.
|
| rdfs:label |
لردليموماب
, Lerdelimumab
|
